Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra, Holly Tovey, Alex Pearson, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223

Showing 1-25 of 223 citing articles:

Pan-cancer landscape of homologous recombination deficiency
Luan Nguyen, John W.M. Martens, Arne van Hoeck, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 370
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 266
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 11, pp. 701-717
Closed Access | Times Cited: 211
Mutational signatures: emerging concepts, caveats and clinical applications
Ching Chiek Koh, Andrea Degasperi, Xueqing Zou, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 619-637
Closed Access | Times Cited: 206
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Hans Petter Eikesdal, Synnøve Yndestad, Ahmed El‐Zawahry, et al.
Annals of Oncology (2020) Vol. 32, Iss. 2, pp. 240-249
Open Access | Times Cited: 161
Mechanism, cellular functions and cancer roles of polymerase-theta-mediated DNA end joining
Dale A. Ramsden, Juan Carvajal-Garcia, Gaorav P. Gupta
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 2, pp. 125-140
Closed Access | Times Cited: 152
PARP inhibition in breast cancer: progress made and future hopes
Nadine Tung, Judy E. Garber
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
Karama Asleh, Nazia Riaz, Torsten O. Nielsen
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 90
Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism
Yiheng Lan, Zhen Xia, Qizhe Shao, et al.
Cell (2025)
Closed Access | Times Cited: 1
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Roman M. Chabanon, Daphné Morel, Thomas Eychenne, et al.
Cancer Research (2021) Vol. 81, Iss. 11, pp. 2888-2902
Open Access | Times Cited: 85
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Alba Llop‐Guevara, Sibylle Loibl, Guillermo Villacampa, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1590-1596
Open Access | Times Cited: 79
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
Lisa Agnello, Silvia Tortorella, Annachiara d’Argenio, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 69
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Parasvi S. Patel, Arash Algouneh, Razqallah Hakem
Oncogene (2021) Vol. 40, Iss. 17, pp. 3001-3014
Closed Access | Times Cited: 65
Therapeutic and prognostic insights from the analysis of cancer mutational signatures
Samuel W. Brady, Alexander M. Gout, Jinghui Zhang
Trends in Genetics (2021) Vol. 38, Iss. 2, pp. 194-208
Open Access | Times Cited: 65
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara, et al.
Cancer Research (2022) Vol. 82, Iss. 8, pp. 1646-1657
Open Access | Times Cited: 64
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Negesse Mekonnen, Hobin Yang, Young Kee Shin
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 55
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
JAMA Oncology (2022) Vol. 8, Iss. 12, pp. 1802-1802
Open Access | Times Cited: 47
Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images
Tristan Lazard, Guillaume Bataillon, Peter Naylor, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100872-100872
Open Access | Times Cited: 46
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Anna Sokolova, Kate Johnstone, Amy E. McCart Reed, et al.
Histopathology (2022) Vol. 82, Iss. 1, pp. 70-82
Open Access | Times Cited: 38
Precision cancer medicine: Concepts, current practice, and future developments
Anders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 455-481
Open Access | Times Cited: 22
Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology
Ben Kinnersley, Amit Sud, Andrew Everall, et al.
Nature Genetics (2024) Vol. 56, Iss. 9, pp. 1868-1877
Open Access | Times Cited: 11
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing
Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, et al.
Genes (2024) Vol. 15, Iss. 2, pp. 219-219
Open Access | Times Cited: 10
Radiomics in breast cancer: Current advances and future directions
Ying-Jia Qi, Guan-Hua Su, Chao You, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101719-101719
Open Access | Times Cited: 10
Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine C. Fuh, Mary M. Mullen, Barbara Blachut, et al.
Gynecologic Oncology (2020) Vol. 159, Iss. 3, pp. 877-886
Closed Access | Times Cited: 56
Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies
Colin Stok, Yannick P. Kok, Nathalie van den Tempel, et al.
Nucleic Acids Research (2021) Vol. 49, Iss. 8, pp. 4239-4257
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top